文献速递瓣膜病与结构性心脏病心律失常

阿哌沙班与标准治疗在TAVI术后的比较:ATLANTIS试验

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.
PubMed 文献 · Eur Heart J · 2022-01-01

ATLANTIS是一项国际随机开放标签优效性试验,纳入1500例成功接受经导管主动脉瓣植入术(TAVI)的患者,比较阿哌沙班与标准治疗。结果显示,阿哌沙班在主要复合终点上不优于标准治疗(18.4% vs 20.1%,HR 0.92,95%CI 0.73-1.16)。

要点

  • TAVI术后阿哌沙班主要复合终点不优于标准治疗。
  • 主要安全终点两组相似(HR 1.02)。
  • 无需长期抗凝者中阿哌沙班降低瓣膜血栓但非心血管死亡信号偏高。

核心结论

  • TAVI术后阿哌沙班不优于标准治疗,无论是否有口服抗凝指征。

研究设计与样本

  • 国际随机开放标签优效性试验,1500例成功TAVI患者1:1随机至阿哌沙班或标准治疗。
  • 随机按需长期抗凝分层: stratum 1接受维生素K拮抗剂(VKA),stratum 2接受抗血小板治疗。

主要发现

  • 主要终点(死亡、心梗、卒中/TIA、系统性栓塞、心内或生物瓣血栓、深静脉血栓或肺栓塞、危及生命/致残/大出血)1年发生率:阿哌沙班组18.4% vs 标准治疗组20.1%,HR 0.92(95%CI 0.73-1.16),治疗与分层无交互作用(Pinteraction=0.57)。
  • 主要安全终点(大出血、致残或危及生命出血)两组相似,HR 1.02(95%CI 0.72-1.44)。
  • Stratum 1(n=451)探索性分析显示阿哌沙班与VKA所有终点无差异。
  • Stratum 2(n=1049)主要终点和主要安全终点无差异,但阿哌沙班 vs 抗血小板治疗降低阻塞性瓣膜血栓(HR 0.19;95%CI 0.08-0.46),并观察到非心血管死亡信号较高。

关键数值与推荐

  • 阿哌沙班剂量:5 mg每日两次(肾功能受损或联用抗血小板时2.5 mg每日两次)。
  • 主要终点1年发生率:阿哌沙班18.4% vs 标准治疗20.1%,HR 0.92(95%CI 0.73-1.16)。
  • 主要安全终点HR 1.02(95%CI 0.72-1.44)。
  • Stratum 2阻塞性瓣膜血栓HR 0.19(95%CI 0.08-0.46)。

临床怎么用

  • TAVI术后常规使用阿哌沙班替代标准治疗未显示优效性。
  • 对于无需长期抗凝的患者,阿哌沙班可减少阻塞性瓣膜血栓但需关注非心血管死亡信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The respective roles of oral anticoagulation or antiplatelet therapy following transcatheter aortic valve implantation (TAVI) remain debated. ATLANTIS is an international, randomized, open-label, superiority trial comparing apixaban to the standard of care. METHODS AND RESULTS: After successful TAVI, 1500 patients were randomized (1:1) to receive apixaban 5 mg (2.5 mg if impaired renal function or concomitant antiplatelet therapy) (n = 749) twice daily, or standard of care (n = 751). Randomization was stratified by the need for chronic anticoagulation therapy. Standard-of-care patients received a vitamin K antagonist (VKA) (Stratum 1) or antiplatelet therapy (Stratum 2) if there was an indication for anticoagulation or not, respectively. The primary endpoint was the composite of death, myocardial infarction, stroke or transient ischaemic attack, systemic embolism, intracardiac or bioprosthesis thrombosis, deep vein thrombosis or pulmonary embolism, and life-threatening, disabling, or major bleeding over 1-year follow-up. The primary safety endpoint was major, disabling, or life-threatening bleeding. The primary outcome occurred in 138 (18.4%) and 151 (20.1%) patients receiving apixaban or standard of care, respectively [hazard ratio (HR) 0.92; 95% confidence interval (CI) 0.73-1.16] and there was no evidence of interaction between treatment and stratum (Pinteraction = 0.57). The primary safety endpoint was similar in both groups (HR 1.02; 95% CI 0.72-1.44). In Stratum 1 (n = 451), an exploratory analysis showed no difference for all endpoints between apixaban and VKA. In Stratum 2 (n = 1049), the primary outcome and primary safety endpoint did not differ, but obstructive valve thrombosis was reduced with apixaban vs. antiplatelet therapy (HR 0.19; 95% CI 0.08-0.46), while a signal of higher non-cardiovascular mortality was observed with apixaban. CONCLUSION: After TAVI, apixaban was not superior to the standard of care, irrespective of an indication for oral anticoagulation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022. PMID: 35583186. doi:10.1093/eurheartj/ehac242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。